PositoAI/ US/ Immuneering Corporation

Immuneering Corporation

NasdaqGM: IMRX · Healthcare

Positivity Index

#2,313 / 6,775

Global

#681 / 3,999

United States

Positivity Score

21,698

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Immuneering Corporation — Overview & Financial Snapshot

Immuneering Corporation (NasdaqGM: IMRX) is a Healthcare company, ranked #2,313 of 6,775 companies globally and #681 of 3,999 in United States on PositoAI, with a Positivity Score of 21,698. Its market capitalisation is ₹2,287.30 Cr ($241.32M), P/E ratio is -4.0 and P/B ratio is 1.27. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #7 Impact BioMedical Inc. 26,324 #13 Onconetix, Inc. 25,899 #16 Revelation Biosciences, Inc. 25,763 #17 BioStem Technologies, Inc. 25,743

— Nothing to show —

OpenAI is reading recent news...

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

P/B Ratio 1.27

P/E Ratio -4.0

D/E Ratio 0.02

ROE -52.15%

Owes vs Owns ? 0.06× Low $0.06 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-88.15$-0.93

Forward EPS ₹-119.02$-1.26

Beta 0.46

Market Cap ₹2,287.30 Cr$241.32M

What these numbers mean →

What does Immuneering Corporation do?

What is Immuneering Corporation's P/E and P/B ratio?

Immuneering Corporation has a P/E ratio of -4.0 and a P/B ratio of 1.27.

What is Immuneering Corporation's debt-to-equity ratio?

Immuneering Corporation has a debt-to-equity ratio of 0.02.

How much does Immuneering Corporation owe compared with what it owns?

Immuneering Corporation owes $0.06 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Immuneering Corporation's Positivity rank?

Immuneering Corporation is ranked #2,313 of 6,775 companies globally and #681 of 3,999 in United States on PositoAI, with a Positivity Score of 21,698.

Does Immuneering Corporation have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Immuneering Corporation.

Where can I read the latest news about Immuneering Corporation?

Recent headlines about Immuneering Corporation from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Immuneering Corporation have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Immuneering Corporation's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.